BPGbio reported encouraging Phase 2 results for BPM31510 in newly diagnosed glioblastoma, showing a 19.3-month median overall survival and 29.3 months in MGMT unmethylated patients at ASCO 2026
Written By: Fariha Sameen, PharmD
Reviewed By: Pharmacally Editorial Team
BPGbio has reported encouraging preliminary findings from its ongoing Phase 2 trial evaluating BPM31510 in combination with standard radiation therapy (RT) and temozolomide (TMZ) for patients with newly diagnosed glioblastoma multiforme (GBM). The results, presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, suggest the investigational therapy may improve survival, particularly in patients with MGMT unmethylated tumors, a subgroup with historically poor outcomes.
The multicenter Phase 2 trial (NCT04752813) enrolled treatment-naïve adults with newly diagnosed GBM. Patients received BPM31510, a lipid nano dispersion formulation of oxidized coenzyme Q10 (CoQ10) administered with vitamin K1, as neoadjuvant and concurrent treatment alongside standard RT and TMZ.
BPM31510 Targets Tumor Mitochondrial Metabolism
Glioblastoma remains the most aggressive primary brain tumor in adults, with limited long-term survival despite surgery, radiation, and chemotherapy. Patients whose tumors lack MGMT promoter methylation typically respond poorly to temozolomide and face significantly shorter survival, highlighting a major unmet clinical need.
BPM31510 targets mitochondrial dysfunction within the tumor microenvironment by modulating oxidative phosphorylation and reactive oxygen species (ROS) production. The therapy aims to restore apoptotic signaling in cancer cells while preserving normal cellular metabolism in healthy tissues.
Phase 2 Trial Demonstrates Encouraging Overall Survival
Among 39 evaluable patients, the preliminary analysis reported a median overall survival (OS) of 19.3 months.
The strongest survival signal emerged in the MGMT unmethylated cohort, where 24 patients achieved a preliminary median OS of 29.3 months. According to BPGbio, this compares favorably with historical survival estimates of approximately 7 to 15.5 months for this high-risk population.
In patients with MGMT methylated tumors, the median overall survival has not yet been reached, reflecting continued survival among many participants at the time of analysis.
Investigators emphasized that these findings remain preliminary, with patient follow-up continuing and the final audited analysis still pending.
The study also met an important safety objective. BPM31510 was generally well tolerated in combination with standard chemoradiation, and investigators reported no new drug-related serious adverse events in the frontline treatment setting.
Leadership Highlights Survival Trends
Niven R. Narain, Ph.D., President and CEO of BPGbio, said the maturing dataset continues to strengthen confidence in the therapy’s potential, particularly in patients with MGMT unmethylated glioblastoma. He noted that the findings support mitochondrial metabolism as a promising therapeutic target for aggressive solid tumors and reaffirm the company’s plans to advance the program toward its final clinical readout.
The study was presented by principal investigator Dr. Seema Nagpal, Professor of Neurology and Neurological Sciences at Stanford University School of Medicine, in an ASCO poster titled “Trial in Progress: Update on a Phase 2 Study of BPM31510 (a Lipid Nanodispersion of Oxidized CoQ10) with Vitamin K in Combination with Standard of Care RT and TMZ in Glioblastoma (GBM) Patients Without Prior Therapy” (Abstract TPS2101).
Regulatory Path Forward
The Phase 2 study has completed enrollment with 51 patients across leading U.S. cancer centers. BPGbio expects to report fully audited topline results in late fall 2026 and plans to present more mature efficacy and safety data at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid. The upcoming analyses will determine whether the encouraging preliminary survival findings can support further clinical development of BPM31510 in newly diagnosed glioblastoma.
Reference
About the Writer
Fariha Sameen, PharmD (LinkedIn), is a clinical pharmacy professional with hands-on experience in patient counselling, medication review, therapeutic monitoring, and clinical documentation across multiple departments. She has experience identifying and assessing drug-related problems and supporting medication safety practices. Her interests include pharmacovigilance, ADR reporting, clinical research, and medical writing focused on clear, evidence-based communication.